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ABSTRACT The isolation of genes from a given genomic
region can be a rate-limiting step in the discovery of disease
genes. We describe an approach to the isolation of cDNAs that
have sequences in common with large genomic clones such as
bacterial artificial chromosomes. We applied this method to
loci both amplified and deleted in cancer, illustrating its usage
in the identification of both oncogenes and tumor suppressor
genes, respectively. The method, called rapid isolation of
cDNAs by hybridization (RICH), depends on solution hybrid-
ization, enzymatic modification, and amplificationyselection
of sequences present in both cDNA populations and the
genomic clones. The method should facilitate the development
of transcription maps for large genomic clones, possibly even
yeast artificial chromosomes.
Powerful methods have facilitated the localization of disease
genes to regions of the genome. Typically, candidate regions are
contained on large yeast or bacterial cloning vectors, and these
vectors must be searched assiduously by various means for
candidate genes. This step has often proved to be an obstacle in
gene discovery. The problem has been attacked in roughly three
ways: by hybridization (1–3), sequence analysis (4, 5), and exon
trapping methods (6–8). Each method has its own particular
advantages, but no current method is without serious problems.
We present herein a method we call rapid isolation of
cDNAs by hybridization (RICH) based on the identification of
sequences in common between a cDNA library and a large
clone of genomic DNA. The method selects and amplifies
those restriction endonuclease fragments of cDNAs that hy-
bridize precisely at one end to the end of a similarly cleaved
genomic DNA fragment. Before hybridization, the cDNA and
genomic fragments are modified with different adaptors.
Those cDNAs that form hybrids with genomic DNA at at least
one end are ligated to a ‘‘selection adaptor’’ that is comple-
mentary to the genomic adaptor and contains an additional
sequence complementary to an RNA polymerase site. Such
cDNAs can be selectively amplified by successive treatments
with RNA and DNA polymerases.
We illustrate the basic method with two series of experi-
ments: (i) a search for transcripts from the c-MYC locus in
cDNAs from a breast cancer cell line and (ii) a search for
transcripts from the PTEN tumor suppressor locus in cDNAs
from normal breast tissue. Although the method is complex, in
that many different enzymes (restriction endonucleases, var-
ious DNA ligases, RNA polymerase, various DNA endo- and
exonucleases, reverse transcriptase, and various DNA poly-
merases) are used, they are all robust enzymes that are readily
available. Only 3 days are required to yield candidates for
further study.
MATERIALS AND METHODS
Materials. The oligonucleotides which were synthesized for
this research are listed in Table 1 and obtained from Biosyn-
thesis (Lewisville, TX). P1 clone 8001 (Genome Systems, St.
Louis) is an 80-kb genomic clone that contains the exons 1–3
of the c-MYC gene. A bacterial artificial chromosome (BAC)
clone, 60C5, containing exons 4–9 of PTEN (containing
nucleotides 1,244–2,246 of the published cDNA, GenBank
accession no. U92436) was obtained from Genome Systems.
The plasmid pUC18, digested with BamHI and treated with
bacterial alkaline phosphatase was supplied by Amersham.
pCR-Script SK(1) and Epicurian Coli XL2-Blue cells were
obtained from Stratagene. SKBr3 is a breast cancer cell line
from which the poly(A)1 RNA was extracted with the Fast-
Track kit (Invitrogen). cDNA was synthesized from the
poly(A)1 RNA of SKBr3 and commercially available poly(A)1
RNA of mammary gland tissue (CLONTECH) by using the
Copy kit (Invitrogen). The Megascript kit was from Ambion
(Austin, TX).
The enzymes and their specific buffers used in RICH were
obtained from the following suppliers: Sau3AI and T4 DNA
ligase from New England Biolabs; Stoffel fragments, Ampli-
Taq, and AmpliTaq Gold from Perkin–Elmer; Ampligase from
Epicentre Technologies (Madison, WI); Pfu DNA Polymerase
and RNase-free Dnase from Stratagene; and l exonuclease
from Amersham.
Glycogen was obtained from Boeringer Mannheim.
GeneQuant G-50, S-300HR, and S-400HR columns and
Sephaglas BandPrep kit were obtained from Amersham.
RNase-free water was supplied by Ambion. Maxi prep kit was
supplied by Qiagen (Hilden, Germany). Phenol was prepared
as described elsewhere (9).
RICH Standard Protocol. To facilitate description of the
RICH protocol, we have broken up the procedure into discrete
units, labeled those units with an alphabetic letter, and assigned
that letter both to the procedure and its final product (Fig. 1).
A. Preparation of genomic DNA. For the preparation of
genomic DNA, 1 mg of BAC DNA is digested with 20 units of
Sau3AI. The digests are purified by phenolychloroform ex-
traction and ethanol precipitation. The whole digests are
mixed with 100 pmol of pR-24 and 100 pmol of R-12 oligo-
nucleotides (Table 1) in 20 ml of 13 T4 DNA ligase buffer. The
double-strand cDNA and the oligonucleotides are heated at 65°C
for 5 min, annealed by cooling down the mixture to 4°C gradually,
and then ligated by overnight incubation with 2,000 units of T4
DNA ligase at 11°C. The excess oligonucleotides are removed
from the ligated fragments with S-400HR columns.
B. Preparation of selection adaptor. The selection adaptor is
synthesized, phosphorylated at its 59end, and purified by
PAGE. The working concentration of the adaptor is 50 nM.
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C. Preparation of cDNA. Double-stranded cDNA is synthe-
sized from 5 mg of poly(A)1 RNA with the Copy kit. One
microgram of cDNA is digested with 20 units of Sau 3AI and
ligated to 100 pmol of pN-24 and 100 pmol of N-12 oligonu-
cleotides in a 20-ml reaction volume as described above. A
partial fill-in mixture is made by combining 21 ml of water, 5
ml of 103 Stoffel buffer, 1 ml of 10 mM dATP, 1 ml of 10 mM
dGTP, and 1 ml of 10 mM dTTP and is added to the ligation
mixture. After incubation at 72°C for 5 min, 2 units of Stoffel
fragment are added to the mixture and incubated at 72°C for
additional 5 min. The fragments are extracted twice with 50 ml
of phenolychloroform. The aqueous phase is transferred to a
new tube.
D. Hybridization. Ten microliters of genomic fragments (com-
ponents A), 5 ml of R(1)SP6 (components B), and 25 ml of cDNA
fragments (components C) are mixed and then extracted twice
with 40 ml of phenolychloroform. Ten microliters of 10 M
ammonium acetate, 1 ml of glycogen (20 mgyml), and 92 ml of
ethanol are added. After centrifugation and washing with 70%
ethanol, the DNA is dissolved in 4 ml of 33 EE buffer (10). The
solution is overlaid with 30 ml of mineral oil and denatured by
incubation in boiling water for 5 min. One microliter of 5 M NaCl
is added and the DNA is reannealed for 16 h at 67°C.
E. Ligation of selection adaptor. To ligate the selection
adaptor to the cDNA fragments, 6 ml of 103 Ampligase buffer
and 1 ml of Ampligase (100 unitsyml) are added to 48 ml of
water, and this ligation mixture is incubated at 67°C for 3 min
before adding to the solution (component D). The total
mixture is then incubated for 4 h at 67°C. After ligation, the
DNA is extracted with 60 ml of phenolychloroform twice,
precipitated by ethanol as above, and dissolved in 50 ml of TE
buffer (10 mM TriszHCl, pH 7.5y1 mM EDTA). Excess
R(1)SP6 is removed by S-400HR after denaturation.
F. Amplification and attenuation. Five microliters of the
DNA solution (component E) is mixed with 50 ml of reaction
mixture [13 AmpliTaq bufferyall four dNTPs (each at 200
nM)y1 mM pN-24y1 mM SP6y1 unit of AmpliTaq Gold]. The
DNA is amplified by a PCR program that specifies an incu-
bation for 10 min at 94°C followed by 10 cycles of 1 min at 94°C,
1 min at 60°C, and 3 min at 72°C. After purification with S-300
HR columns, the DNA is digested at 37°C with 10 units of l
exonuclease. Eighty microliters of TE is added to the reaction
mixture and incubated in boiling water for 5 min. The 100-ml
PCR mixture contains 8 ml of the DNA, all four dNTPs (each
at 200 mM), 1 mM pN-24, 1 mM SP6, and Pfu buffer at a 13
final concentration. After initial denaturation of 94°C for 5
min, 2.5 units of Pfu polymerase is added to the mixture and
20 cycles at 94°C for 1 min and 70°C for 4 min are performed,
followed by a final extension at 72°C for 10 min. The PCR
products are purified with phenolychloroform extraction and
ethanol precipitation. The DNA is dissolved in 25 ml of
RNase-free water after washing with 70% ethanol.
G. RNA transcription and attenuation. RNA is transcribed
from 8 ml of the DNA template (component F) with the
Megascript kit. After a 6-h incubation at 37°C, 20 units of
RNase-free Dnase I is added and the incubation is continued
for an additional 10 min. The RNA is purified with phenoly
chloroform extraction and dissolved in 15 ml of RNase-free
water after ethanol precipitation.
H. Reverse transcription-coupled PCR amplification. To syn-
thesize cDNA, 1.3 ml of 50 mM pN-24 is added to the mixture
(component G), incubated at 65°C for 10 min, and then placed
at room temperature for 5 min. Double-stranded cDNA is
synthesized by the Copy kit following the supplier’s protocol.
After the products are denatured by heating to 94°C for 10 min,
they are purified with S-300HR columns. The 200-ml PCR
mixture contains 10 ml of the cDNA, all four dNTPs (each at
200 mM), 1 mM pN-24, 1 mM pR-24, 5 units of AmpliTaq Gold,
and AmpliTaq buffer at a 13 final concentration. After initial
denaturation of 94°C for 10 min, 30 cycles at 94°C for 1 min and
72°C for 3 min were performed, followed by a final extension
at 72°C for 10 min.
I. Cloning and sequencing. The RICH products were purified
with GeneQuant G-50 columns and digested with 40 units of
Sau3AI in a 120-ml reaction volume at 37°C for 4 h. The digests
were size-fractionated by electrophoresis through an agarose
gel for Southern blot analysis and for cloning. The DNA bands
were excised, purified with the Sephaglas BandPrep kit, and
cloned into pUC18 digested with BamHI and treated with
bacterial alkaline phosphatase. Epicurian Coli XL2-Blue cells
were transformed with the plasmid. The plasmid DNA was
purified with the Maxi prep kit and sequenced by the Cycle
Sequencing system (Perkin–Elmer).
J. Southern blot analysis. A part of RICH product was
electrophoresed through a 4% agarose gel and transferred to
FIG. 1. Flowchart of RICH. Each boldface letter represents a unit
of the RICH procedure described in the standard RICH protocol.
Table 1. Oligonucleotide sequences for RICH
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Hybond N1 (Amersham). Hybridization with the PTEN
cDNA probe was detected by the ECL system (Amersham).
K. Making representations of genomic clones. In one variation
of the basic method, we used representations of genomic
clones. To make the representation, 100 ng of BAC DNA is
digested with 5 units of Sau3AI. The digests are purified by
phenolychloroform extraction and ethanol precipitation. The
whole digests are mixed with 100 pmol of pR-24 and 100 pmol
of R-12 oligonucleotides (Table 1) in 20 ml of 13 T4 DNA
ligase buffer. The double-strand cDNA and the oligonucleo-
tides are heated at 65°C for 5 min, annealed by cooling the
mixture to 4°C gradually, and then ligated by overnight incu-
bation with 2,000 units of T4 DNA ligase at 11°C.
RESULTS
The Basic Method. For convenience, we break the method
into two parts. In part one, we add a selection adaptor to only
those cDNA fragments that hybridize at one end to an end of
a genomic fragment. In part two, we selectively amplify only
those modified cDNA fragments. The complexity of the
method arises from the need to suppress the amplification of
self-annealed cDNA and genomic homoduplexes. Fig. 2 out-
lines the basic schema.
Part One. First, both the large genomic clone and cDNA are
separately cleaved with Sau3AI and modified with T4 DNA
ligase by the addition of oligonucleotide adaptors (pR-24 for
genomic DNA and pN-24 for cDNA) at their 59 ends only.
These adaptors have phosphate groups at their 59 ends, for
reasons that will become apparent in part two.
Next, the 39 ends of the adapted cDNA molecules are
partially filled-in with the three nucleotides guanosine, aden-
osine, and thymidine by using the Stoffel fragment (a Taq
DNA polymerase lacking both 39 and 59 exonuclease activity).
This step enables us to distinguish later the homoduplexes of
genomic DNA from the cDNA–genomic heteroduplexes. An
alternative to partial filling is presented later.
The cDNA and genomic DNAs are mixed at equal mass
ratios, and the selection adaptor pR(1)SP6 is added.
pR(1)SP6 is complementary to pR-24 but has an extra
cytidine at its 59 end and a sequence complementary to the SP6
RNA polymerase promoter sequence at its 39 end.
The mixture is heat-denatured and allowed to reanneal.
During reannealing, two and three part structures will form, as
indicated in Fig. 2 A. The reannealed mixture is treated with a
thermostable DNA ligase, Ampligase, at 68°C to ensure that
perfect matches are preferentially ligated.
Ligation of pR(1)SP6 to cDNA will occur only when the
latter is annealed to a matching genomic fragment, forming a
perfect contiguous substrate for the ligase. The extra cytidine
at the 59 end of pR(1)SP6 is needed to fill the gap of the
partially filled-in cDNA fragment. pR(1)SP6 will not be
ligated to genomic homoduplexes because those three part
structures will have a 3-nucleotide gap. Neither will pR(1)SP6
be ligated to cDNA homoduplex because the latter, lacking
pR-24 and having only a 1-base overhang, will not base-pair to
pR(1)SP6.
Thus only cDNAs with homology to genomic fragments at
one end will have the pN-24 adaptors at their 59 ends and the
pR(1)SP6 selection adaptor at their 39 ends.
Part Two. The selectively modified cDNA fragments are
amplified, in the following manner. First, after ligation, we
denature the mixture and use Taq DNA polymerase and an
oligonucleotide primer containing the SP6 promoter sequence
to make the selectively modified cDNAs double-stranded.
These SP6 primers are not phosphorylated at their 59 ends.
This step is repeated 10 times to give an arithmetic increase in
the number of complementary strands (see Fig. 2B).
Next, the entire mixture is treated with l exonuclease, which
degrades double-stranded fragments from their phosphory-
FIG. 2. RICH procedure. (A) Part 1. (B) Part 2. A circle represents
a phosphorylated 59 end. Open boxes represent filled-in bases. Oli-
gonucleotides and their antisense sequences are drawn as dark and
light shaded boxes.
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lated 59 ends. The strands synthesized from the SP6 primers are
thus protected. A small number of duplexes will be formed
during the reannealing of the previous step and, when filled-in
by Taq polymerase, would contaminate the subsequent reac-
tions. These contaminants are destroyed by l exonuclease
because the adaptors pR-24 and pN-24 have phosphorylated 59
ends.
To amplify the SP6-primed strand, we perform a PCR with
Pfu DNA polymerase and SP6 and pN-24 oligonucleotides as
primers. We use Pfu polymerase because its products are
blunt-ended, whereas Taq polymerase sometimes adds an extra
nucleotide to the 39 end of its product, and the SP6 RNA
polymerase used in the next step does not work well on
substrates with 39 protruding ends.
In this amplification step, it is likely that cDNA homodu-
plexes that escaped l exonuclease treatment will be amplified.
Moreover, a significant amount of genomic homoduplexes
would be amplified in later steps. Therefore, we use SP6 RNA
polymerase (Ambion) to create RNA transcripts of those
molecules that contain the SP6 promoter sequence and digest
any surviving DNA molecules with DNase I.
Finally, reverse transcription with avian myeloblastosis virus
reverse transcriptase (Invitrogen) using pN-24 as primer,
followed by PCR with Taq DNA polymerase and pN-24 and
pR-24 as primers, yields products for cloning and analysis.
Testing the c-MYC Locus. Our first mock experiments, not
shown, used serial dilutions of the bacterial plasmid pUC18
into a cDNA library, and DNA from a 160-kbp BAC (60C5)
to which was added an equimolar amount of the same plasmid.
These experiments demonstrated to our satisfaction that the
procedure would work well with cDNA species containing as
little as 0.01% of a cDNA library. Success of the method was
not evident when the pUC18 was present in cDNA at the
0.0001% level. We proceeded next with actual test cases.
In our first test case, we used an 80-kb P1 bacterial cloning
vector containing the entire c-MYC gene and used randomly
primed double-stranded cDNA that was prepared from the
poly(A)1 RNA of the breast cancer cell line SKBr3, in which the
c-MYC locus is amplified. Northern blot analysis indicated that
the level of c-MYC expression from SKBr3 was in the middle of
the range for a panel of breast cancer cell lines, including BT20,
Du4475, HS578T, MDA134, MDA231, MDA436, SKBr3,
UACC812, UACC893, ZR75–1, and ZR75–30. We estimated
that c-MYC expression was 3-fold higher in SKBR3 than in
normal breast tissue and 3-fold lower than in the highest express-
ing tumor cell line tested, ZR75–30.
Clones were prepared from the RICH products by either
blunt-ended ligation to pCR-Script SK(1) or cleavage with
Sau3AI followed by ligation to pUC18. Vector inserts were
sequenced. All blunt-ended inserts contained both the pN-24 and
pR-24 sequences and the adjoining GATC sequences, indicating
that they all derived from cDNA–genomic heteroduplexes.
cDNA insert sizes varied from 61 to 259 bp. Roughly
one-quarter of clones either had no matches in the data bases
or were repeat sequences, mainly of the alu family. The
remaining three-quarters had identity to sequences found on
c-MYC mRNA, as indicated in Fig. 3. One type of RICH
product derived from exon 1 of c-MYC entirely, one spanned
exons 2 and 3, and two derived entirely from exon 3. Shorter
fragments, less than 100 bp, and a larger fragment, 880 bp
spanning exon 1 and 2, were not obtained in the first 81 clones
examined. No clones from either the 39 or 59 ends of c-MYC
were obtained, and this is predicted by theory because a cDNA
fragment would need to have Sau3AI sites at both ends to be
found.
Testing the PTEN Locus. In a second test of the method, we
used a 160-kb BAC, 60C5, containing PTEN, a tumor sup-
pressor gene that encodes a mixed-specificity protein phos-
phatase expressed ubiquitously but at a low level in normal
tissues (11–13). We prepared double-stranded cDNA from
normal human breast tissue by random priming of poly(A)1
RNA. As a control we used another BAC from a different
region of the genome. By following the same protocol as above,
we obtained RICH products from each BAC and probed the
products with PTEN cDNA by Southern blotting. Only RICH
products from the PTEN BAC yielded fragments that hybrid-
ized with PTEN sequences (Fig. 4). In total at least three
PTEN products were observed, about 200, 350, and 570 bp
long. We expected fragment sizes of 153, 298, and 520 bp
without adaptors and 201, 346, and 568 bp with adaptors, all
of which span exons. We failed to observe a range of smaller
fragments (Fig. 5 and see Discussion).
To estimate the ratio of the products that derived from
PTEN cDNA to products deriving from repeat sequences, a
collection of clones were analyzed by filter hybridization with
both PTEN cDNA and total human DNA as probes. Six of 120
clones hybridized to PTEN cDNA and about 60 hybridized to
total human genomic sequences.
To extend the utility of RICH, we tested a variation in the
method: we used the PCR product from a large insert cloning
vector as our source of genomic DNA. For this purpose, we
gel-purified PTEN BAC and cleaved it with Sau3AI, ligated
pR-24 to the 59 ends, filled-in the 39 ends, and used PCR to
amplify fragments with pR-24 as primer. We used this ampli-
fied material in an otherwise identical protocol and obtained
results that, by Southern blotting, appeared as satisfactory as
when we began with restriction endonuclease-cleaved BAC
DNA.
We analyzed in greater depth the RICH products of this
experiment by blunt-ended cloning into pCR-Script SK(1).
Ninety-six individual clones were analyzed. They were tested for
the presence of inserts by PCR using primers derived from the
FIG. 4. RICH products from the PTEN gene. Lanes: A, RICH
products obtained from the PTEN BAC, 60C5; B, RICH products
from an unrelated BAC; C, pBR322 DNA digested with MspI. Lanes
A and B were transferred to a nylon membrane and probed with PTEN
cDNA (lanes D and E) or total human DNA (lanes F and G). Lanes:
D and F, RICH products from the PTEN BAC; E and G, RICH
products from the unrelated BAC.
FIG. 3. RICH products and the c-MYC gene. Arrows indicate
Sau3AI recognition sites. Shadowed boxes represent RICH products,
the sizes of which are 150, 250, 166, and 135 bp from the left. The large
restriction fragment that we failed to isolate lies between third and
forth arrows from the left and is 880 bp.
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vector cloning sites and for the presence of the Sau3AI sites by
cleavage of the PCR product. By this simple test, only 17 had
Sau3AI sites at the expected sites within the inserts. Sequence
analysis indicated that all 17 of these contained both the pN-24
and pR-24 primers at the proper sites (this could also have been
determined by PCR). Of the 17, five derived from PTEN cDNA,
representing the 153-bp (three times) and the 298-bp (twice)
Sau3AI fragments. The larger fragment, 520 bp long, was not
obtained in this group. The remaining 12 inserts contain a
Sau3AI site within human repeat sequences. Two of these
contained repeats we have not yet found in the sequence of the
PTEN BAC, the sequence of which is now 90% complete.
DISCUSSION
Finding genes in large chromosomal regions has been ap-
proached in three ways: exon trapping, DNA sequencing
analysis, and direct hybridization selection. Exon trapping
works when the gene in question contains splicing sites that are
efficiently recognized by the host cell (6–8). But it fails when
introns are absent or the intron–exon borders are not recog-
nized; and exon trapping yields a background of false candi-
dates derived from cryptic splice sites. DNA sequencing is
effective when the gene in question has homology to a known
expressed sequence. Even without homology, computational
methods for predicting genes also have promise (4). But DNA
sequencing on a massive scale is still costly. Direct hybridiza-
tion selection (1) has also found use, but it diminishes in
usefulness with rare messages and suffers from the vagaries of
physical selection methods and background problems with
repetitive sequences. We have described an additional ap-
proach to this problem: an effective protocol for selecting
cDNA fragments that are homologous at one of their ends to
one of the ends from a collection of genomic fragments. This
method should work whenever a cDNA population is available
that contains transcripts from the gene in question.
A protocol (end ligation coincident sequence cloning, EL-
CSC) similar to ours, has been presented by Brookes et al. (14).
Like ours, their protocol is based upon heteroduplex formation
between DNA fragments made from two populations, and the
use of ligation (with what they call ‘‘capture oligonucleotides’’)
to distinguish heteroduplex from homoduplex. Unlike our
procedure, their method requires heteroduplex formation at
both ends between cDNA and genomic fragments, because
both ends of the heteroduplex must be ligated. Thus, cloning
of cDNA fragments that span introns is much less likely. In our
procedure, we use a selection adaptor that allows us to
generate an RNA intermediate, and so we can isolate hetero-
duplexes that have formed at only one end. Moreover, EL-CSC
uses physical trapping through biotin–avidin complex forma-
tion to enrich for products. We have experienced difficulty
with protocols incorporating such methods and have avoided
them in RICH. The report of Brookes et al. (14) does not
contain sufficient information to enable us to make quantita-
tive comparisons of our methods nor have we found their
procedure used in the published literature.
Although the yield of c-MYC fragments in the RICH
products was very satisfactory, the yield of PTEN products was
less so. An additional prescreening of RICH products from
PTEN was needed: namely, the verification of the adaptors and
the Sau3AI sites that should be present upon proper priming
and ligation. We believe that this is due to the reduced level of
expression of the PTEN gene compared with c-MYC. More-
over, an analysis of our products from the PTEN BAC revealed
a higher proportion of repeat-containing sequences than were
found for c-MYC, presumably for the same reason.
Not all fragments from the same cDNA will have the same
yield. For example, the 880-bp fragment from c-MYC was not
obtained as a RICH product. We speculate this may be due to
the difficulty of obtaining long transcripts from the SP6
polymerase. Also, we did not clone the 520-bp fragment of
PTEN that was seen upon Southern blotting to be present in
reduced amount. Most strikingly, we do not observe very short
fragments in the RICH products. Possibly, this deficit is
partially due to the slower kinetics of hybridization of shorter
fragments (15). Gel fractionation before cloning might over-
come some of these problems of underrepresentation. Alter-
natively, these limitations can be overcome by using different
restriction endonucleases during the protocol.
We have introduced one variation in our method: amplifying
genomic DNA fragments before use. This step was incorpo-
rated for two reasons. (i) If genomic fragments are amplified
and not cleaved, it should be unnecessary to partially fill-in the
ends of restriction endonuclease cleaved cDNA, because the
selection adaptor cannot be ligated to PCR-amplified genomic
DNA. Thus, with this variation, any restriction endonuclease
can be chosen, if used both for cDNA cleavage and amplifi-
cation of genomic fragments, overcoming limitations in the
discovery of cDNAs that might result from the use of Sau3AI
discussed above. (ii) With genomic amplification the user can
initiate the search for transcripts with very small amounts of
genomic DNA. In fact, we have performed RICH starting
from small amounts of gel-purified BAC DNA. It may be
possible to extend this method to gel-purified yeast artificial
chromosome DNAs.
We cannot obtain the 39 or 59 ends of cDNA transcripts with
RICH because only cDNA fragments with restriction endo-
nuclease cleavage sites at both ends can be selectively ampli-
fied. However, RICH can be used in reverse (rapid isolation
of genes by hybridization to transcripts, RIGHT) to identify
genomic clones with homology to cDNAs. The directional
modifications of genomic fragments and cDNAs used in RICH
can be essentially reversed, rendering genomic fragments that
form heteroduplex with cDNA the only selectable RIGHT
products. When unamplified cDNAs are used, the RIGHT
protocol should yield the 39 and 59 ends of a transcription unit.
In addition, RIGHT might facilitate the confirmation of
cDNAs found by RICH and aid in the determination of
intron-exon boundaries.
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